The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trial Details

Back

Molecule overview Clinical trials

Other or Multiple Cancer Types

Mesothelin-Targeted Antibody Drug Conjugate

PF-08052666 (SGN-MesoC2) is an investigational compound. Its safety and efficacy have not been established.

A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SGN-MesoC2 in Subjects With Advanced Solid Tumors

Phase 1

NCT06466187

Active enrolling

Locations

United States

Scan the QR code

for more information at clinicaltrials.gov

Share to an HCP Contact Us

Study design Key eligibility criteria Key dates Key endpoints Number of participants Collaborators and investigators

Share to an HCP Contact Us

Study design

Participant Group/Arm

EXPERIMENTAL: SGN-MesoC2

SGN-MesoC2 monotherapy

Intervention/Treatment

DRUG: SGN-MesoC2

Given into the vein (IV; intravenously)

Study design table for Clinical Trial

Key eligibility criteria

Inclusion criteria

An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
Participants must have histologically- or cytologically-confirmed metastatic or locally advanced unresectable ovarian cancer, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma, colorectal cancer (CRC), mesothelioma, or other solid tumors, have relapsed or progressed following standard therapies, or for which no standard therapy is available.
Must have at least one measurable lesion at baseline based on RECIST v1.1.
Archival tumor tissue is required, or, if unavailable, a fresh tumor biopsy (if it is safe and feasible) during the screening period.
Participants weighing ≥40 kg
Additional inclusion criterion for platinum resistant ovarian cancer (PROC) participants: Histologically or cytologically documented invasive epithelial ovarian, primary peritoneal, or fallopian tube cancer (tumors with pseudomyxomatous or mucinous histology are excluded) or advanced predominantly epithelioid peritoneal, must have relapsed or progressed following local standard therapies or for which no standard therapy is available.
Platinum prior exposure unless it is contraindicated or not available.
Participants with known FRa high expression, must have progressed after mirvetuximab soravtansine (if available or other FRa-directed therapy) unless contraindicated or not available.
Additional inclusion criterion for pancreatic ductal adenocarcinoma (PDAC) participants: Histologically or cytologically documented, locally advanced unresectable or metastatic pancreatic adenocarcinoma, including recurrence of previously resected disease.
Participant must have progressed after standard cytotoxic therapies, or for which no standard therapy is available. Participants must have received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, gemcitabine and nab-paclitaxel combination or gemcitabine-based chemotherapy.
Additional inclusion criterion for NSCLC participants: Histologically or cytologically confirmed advanced and/or metastatic NSCLC, must have progressed after standard therapies, or for which no standard therapy is available.
If participants have a specific mutation for which standard therapy is available (eg, ALK, ROS1, MET, NTRK, BRAF V600E, EGFR Exon 20 ins, RET, KRAS G12C, HER2), they must have documented progression after treatment with appropriate tyrosine kinase inhibitor or other agent and have documented progression after platinum doublet chemotherapy treatment, unless not tolerated, contraindicated, or not available.
Additional inclusion criterion for CRC participants: Histologically confirmed metastatic or locally advanced colorectal adenocarcinoma.
Participant must have progressed after standard therapy, or for which no standard therapy is available. Participants must have received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, unless not tolerated, contraindicated, or not available.
Participants with microsatellite instability (MSI)-H/mismatch repair deficient (dMMR) tumors must have received treatment with a PD-1 mAb, unless not tolerated or available. If participants have an BRAF mutation or other mutations, they must have documented progression after treated with appropriate therapies (eg, encorafenib + cetuximab), unless not tolerated or available. Particpants with HER2 positive tumors, must have received treatment with HER2-directed therapies (eg, tucatinib + trastuzumab), unless not tolerated or available.
Additional inclusion criteria for EC participants: Participant must have received at least 1 line of platinum-based chemotherapy.
Participant must have received up to 2 lines of systemic therapy in metastatic setting.
If appropriate by biomarker status (including but not limited to microsatellite instability \[MSI\] and dMMR status) and available per local SOC, must have received a prior PD-1 inhibitor and/or the combination of pembrolizumab and lenvatinib, unless not tolerated.
Additional inclusion criteria for mesothelioma participants: Histologically or cytologically confirmed advanced and/or metastatic mesothelioma, must have progressed after standard therapies, or for which no standard therapy is available.

Exclusion criteria

Participants previously received or is currently receiving the following anticancer medications or investigational drugs will be excluded:
- Any systemic anticancer therapy or focal radiotherapy within 4 weeks prior to first dose of SGN-MesoC2 or within 2 weeks prior to the first dose of SGN-MesoC2 if the underlying disease has progressed on treatment.
- For Part C, prior anti-Mesothelin (MSLN) antibody (mAb or BsAb), MSLN-directed AD
Major surgery (excluding placement of vascular access) within 4 weeks, or minor surgery within 7 days, prior to first dose of study intervention. Participants must have recovered adequately from the toxicity or complications from the surgery prior to starting SGN-MesoC2. Participants who have planned major surgery during the treatment period must be excluded from the study.
History of another malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.
Known to be positive for human immunodeficiency virus (HIV). Participants with severe or uncontrolled systemic diseases, including uncontrolled hypertension, uncontrolled diabetes mellitus, or active bleeding diatheses.
Participants with medical history of clinically significant lung diseases (eg, interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or who are suspected to have these diseases by imaging at screening period.
Previously untreated brain metastases. Participants who have received radiation or surgery for brain metastases are eligible if therapy was completed at least 4 weeks prior to initiation of study treatment, there is no evidence of central nervous system (CNS) disease progression, and there is no requirement for chronic corticosteroid therapy. Leptomeningeal metastases or spinal cord compression due to disease.

Key dates

Study start date

August 2024

Estimated Study Completion Date

November 2028

Key endpoints

Primary Outcome Measures

Outcome Measure

Number of participants with adverse events (AEs)

Measure Description

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time Frame

Through 30-37 days after the last dose of study treatment, 48 Months

Outcome Measure

Number of participants with laboratory abnormalities

Measure Description

Time Frame

Through 30-37 days after the last dose of study treatment, 48 Months

Outcome Measure

Number of participants with dose modifications

Measure Description

Frequency of dose modifications (eg, dose delay, treatment interruptions, dose reductions and treatment discontinuations) due to AEs

Time Frame

Up to 4 months

Outcome Measure

Number of participants with dose-limiting toxicities (DLTs)

Measure Description

Incidence of dose-limiting toxicities (DLTs)

Time Frame

Cycle 1 (21 days)

Primary Outcome Measures table for Clinical Trial

Secondary Outcome Measures:

Outcome Measure

Objective response rate (ORR)

Measure Description

ORR is defined as the proportion of participants in the relevant analysis set with best response of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

Time Frame

Approximately 1 year 4 months

Outcome Measure

Best response

Measure Description

The best timepoint response achieved for the subject during the protocol specified period according to RECIST V1.1.

Time Frame

Approximately 1 year 4 months

Outcome Measure

Duration of response (DOR)

Measure Description

DOR is defined as the time interval from first occurrence of documented objective response to the time of progressive disease (PD) according to RECIST v1.1 or death from any cause, whichever comes first.

Time Frame

Approximately 1 year 4 months

Outcome Measure

Disease control rate (DCR)

Measure Description

DCR is defined as the proportion of participants with best response of CR, PR or stable disease (SD) according to RECIST v1.1.

Time Frame

Approximately 1 year 4 months

Outcome Measure

Progression-free survival (PFS)

Measure Description

PFS is defined as the time from first dosing to the first occurrence of PD according to RECIST v1.1 or death from any cause, whichever comes first.

Time Frame

Approximately 1 year 4 months

Outcome Measure

Overall survival (OS)

Measure Description

Overall survival (OS) defined as the time from first dosing to death.

Time Frame

Approximately 1 year 4 months